Financials
Financial year 2025
Vascular Research Center Bonheiden from Herenthout, company number BE0677749094, closed financial year 2025 with a result of € 47,516 after tax. For that financial year Vascular Research Center Bonheiden recorded a gross margin of € 111,925 and equity of € 66,964. Compared with financial year 2024, the result moved from € -10,042 to € 47,516. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 24, 2026.
€ 66,964
▼ 31% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 47,516
▲ still € 10,042 loss in 2024
Profit after tax over the fiscal year.
€ 134,084
▲ 59% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 75,000 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 49,285
▲ 10% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 30
Supplier invoices still open on the last day of the fiscal year.
€ 15,378
▲ 242% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 67,050 | € 74,121 | € 35,160 | € 111,925 | ▲ 218% |
| Profit after taxes | € 18,429 | € 13,738 | € -10,042 | € 47,516 | ▲ € 57,557 |
| Equity | € 92,252 | € 106,990 | € 96,948 | € 66,964 | ▼ 31% |
| Total debts | € 5,277 | € 1,757 | € 4,678 | € 92,908 | ▲ € 88,230 |
| Cash | € 79,655 | € 94,185 | € 84,451 | € 134,084 | ▲ 59% |
| Retained profit | € 90,252 | € 103,990 | € 93,948 | € 63,964 | ▼ 32% |
| Dividend | € 0 | € 0 | € 0 | € 75,000 | |
| Balance sheet total | € 97,529 | € 108,748 | € 101,626 | € 159,871 | ▲ 57% |
Key figures of Vascular Research Center Bonheiden, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Vascular Research Center Bonheiden?
What happened at Vascular Research Center Bonheiden in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 47,516. filed late Source: NBB ↗
- Fien Gryffroy became a director. NBB
- New establishment in Herenthout. KBO
- Jürgen Torsten Verbist became a director. NBB
- Wouter Van Den Eynde became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 18,429 profit in 2022 to € 47,516 profit in 2025.
Paid € 29,830 in corporate taxes since 2022.
Best year ever: 2025, with € 47,516 profit.
Paid out € 75,000 in dividends to the owners in total.
A new publication or filing at Vascular Research Center Bonheiden? We notify you, reason included.
Follow Vascular Research Center BonheidenDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Dokter Wouter Van den Eynde, Dokters J.Verbist & O.Verdoes comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Vascular Research Center BonheidenBehind Vascular Research Center Bonheiden are Jürgen Torsten Verbist, Wouter Van Den Eynde and Fien Gryffroy. The shares are held by Dokter Wouter Van den Eynde (50%) and Dokters J.Verbist & O.Verdoes (50%).
Directors
According to the 2025 annual accounts
Jürgen Torsten Verbist
Director
since 2017
since 2017
since 2023
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Canadadreef 34
2270 Herenthout
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0677.749.094
- VAT number
- BE 0677.749.094
- Registered office
- Canadadreef 34, 2270 Herenthout
- Names & denominations
- Vascular Research Center Bonheiden
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 30 June 2017
- Peppol
- Active · Active since 26 Nov 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied